Bordetella bronchiseptica, a small, pleomorphic, gramnegative coccobacillus, causes atrophic rhinitis in swine, snuffles in rabbits, and kennel cough in dogs (10, 18) . Humans, however, are rarely infected with this organism. When infections in humans occur, they are often acquired through animal contact and typically involve immunocompromised patients (18). The spectrum of immunocompromised patients who have developed B. bronchiseptica infection includes patients with malignancies such as Hodgkin's disease (17) or chronic lymphocytic leukemia (1) , one cardiac transplantation patient (4), one patient with AIDS (7), and debilitated alcoholics (9, 12 Microbiologic investigation. Antimicrobial susceptibility testing by the Kirby-Bauer disk method showed the original B. bronchiseptica isolate from the BAL specimen to be susceptible to amikacin, cefoperazone, ceftazidime, imipenem, mezlocillin, piperacillin, ticarcillin-clavulanate, ciprofloxacin, trimethoprim-sulfamethoxazole, polymyxin B, and tobramycin. Broth dilution MICs and MBCs were performed on the initial isolate obtained from the BAL specimen and the first isolate obtained from blood. The MICs of ciprofloxacin for the two isolates were 0.25 and 1.0 ,ug/ml, respectively. The MBCs were 0.5 and >1.0 ,g/ml, respectively. The MICs of doxycycline for the two isolates were 0.125 and 4.0 pg/ml, respectively; the MBCs were >4.0 and >32 p,g/ml, respectively. Synergy testing by the checkerboard method (13) showed that the combination of ciprofloxacin and doxycycline exhibits antagonism at both the inhibitory and bactericidal levels.
Twenty-five cases of B. bronchiseptica infection have previously been described in humans (18). Among these patients, the respiratory tract has most frequently been involved, with a range of clinical manifestations such as sinusitis, tracheobronchitis, whooping cough, and pneumonia being noted (18). Radiographic appearances of lower respiratory tract infections have included diffuse infiltrates (1), interstitial pneumonia (4), and lobar pneumonia (14) . Seven cases of bacteremia, including two cases of endocarditis (11, 15) and two cases of concomitant pneumonia (8, 9) , have been attributed to B. bronchiseptica infections (6, 8, 11, 12, 16) . Other clinical manifestations have included peritonitis and meningitis (2, 3) .
The optimal therapy for B. bronchiseptica infections has not been established. In vitro susceptibility testing may not correlate with in vivo efficacy. Nevertheless, recent in vitro antimicrobial susceptibility testing suggests that aminoglycosides, antipseudomonal penicillins, tetracyclines, and chloramphenicol are the most effective agents (18). Some difficulty in treating B. bronchiseptica may occur because Bordetella species produce an enzyme, adenylate cyclase, that enters host polymorphonuclear cells and macrophages and disrupts chemotaxis, superoxide production, and bacterial killing (5) .
The patient we describe represents the first report of B. bronchiseptica infection following bone marrow transplantation. Our patient's history suggested that her infection began as an upper respiratory tract infection acquired through contact with an ill dog. Her infection progressed to pneumonia and bacteremia. The persistence of her infection occurred despite antimicrobial therapy and may have resulted from a combination of the following three factors: the patient's underlying immunosuppression, the ability of B. bronchiseptica to inhibit leukocyte function, and antimicrobial antagonism between ciprofloxacin and doxycycline. The contribution of each of these factors is uncertain; but given the patient's persistent immunosuppression and the failure of multiple antibiotics, including imipenem, tobramycin, ciprofloxacin, and doxycycline, it is likely that the immunosuppression played the most important role. The course of infection in the patient described here illustrates the potential seriousness of B. bronchiseptica infections in immunosuppressed hosts and suggests that treatment of B. bronchiseptica infections with combined antimicrobial therapy may, in certain instances, contribute to a poor clinical outcome. Physicians should be aware of the potential for B. bronchiseptica infections in immunosuppressed patients who have contact with sick pets.
